Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
18.1
Price to sales ratio
5.23
Dividends per share
3.16
Dividend yield %
2.57

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
44
NVS
Novartis AG
153.53 USD-0.34%-1.32%-0.31%+27.51%292.96 B USD
71
AMGN
Amgen Inc. - Common Stock
360.45 USD-0.81%-3.70%+2.19%+22.66%194.54 B USD
109
PFE
Pfizer, Inc. Common Stock
24.45 USD+1.07%+2.64%-7.00%-4.42%139.35 B USD
127
BMY
Bristol-Myers Squibb Company Common Stock
59.37 USD+3.14%+2.73%+4.40%+26.67%121.24 B USD

Frequently asked questions about Gilead Sciences, Inc. - Common Stock

What is the Gilead Sciences, Inc. - Common Stock stock price today?

The current price of Gilead Sciences, Inc. - Common Stock (GILD) is 131.4. Over the past 24 hours, the stock has changed by +1.21%. Follow the GILD chart for real-time price dynamics.

What is the stock ticker of Gilead Sciences, Inc. - Common Stock?

Gilead Sciences, Inc. - Common Stock trades under the ticker GILD. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Gilead Sciences, Inc. - Common Stock stock going up?

GILD has changed by -0.92% over the last week, +3.87% over the last month, and +19.70% over the last year. Review the chart to see whether the current move is part of a broader trend.

Does Gilead Sciences, Inc. - Common Stock release financial reports?

Yes. You can track Gilead Sciences, Inc. - Common Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What was Gilead Sciences, Inc. - Common Stock net income for the last quarter?

Gilead Sciences, Inc. - Common Stock reported net income of 2.02 B for the last quarter. The previous quarter showed 2.18 B, which means net income changed by -7.42%.

How many employees does Gilead Sciences, Inc. - Common Stock have?

As of the latest available data, Gilead Sciences, Inc. - Common Stock has 17 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Gilead Sciences, Inc. - Common Stock EBITDA?

Gilead Sciences, Inc. - Common Stock EBITDA is 3.27 B, and its EBITDA margin is 47.05%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Gilead Sciences, Inc. - Common Stock stock?

You can buy Gilead Sciences, Inc. - Common Stock (GILD) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Gilead Sciences, Inc. - Common Stock stock?

Investing in Gilead Sciences, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the GILD chart and related analysis on metatrader.com as part of your research.

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

News